ML-007

ML-007
Clinical data
Other namesML007; ML-007/PAC; ML007/PAC
Routes of
administration		Oral[1]
Drug classMuscarinic acetylcholine M1 and M4 receptor agonist[1]

ML-007 is a selective muscarinic acetylcholine M1 and M4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias.[1][2][3][4] It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC).[4][3] The drug is taken by mouth.[1]

As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias.[1][2][3] It is under development by MapLight Therapeutics.[1][2] The drug is a small molecule, but its chemical structure does not seem to have been disclosed.[4][1][2]

See also

References

  1. ^ a b c d e f g "ML 007". AdisInsight. Springer Nature Switzerland AG. 9 January 2024. Retrieved 21 October 2024.
  2. ^ a b c d "Delving into the Latest Updates on ML-007 with Synapse". Synapse. 19 September 2024. Retrieved 21 October 2024.
  3. ^ a b c Yohn SE, Harvey PD, Brannan SK, Horan WP (4 October 2024). "The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia". Frontiers in Psychiatry. 15. Frontiers Media SA. doi:10.3389/fpsyt.2024.1421554. ISSN 1664-0640. PMC 11525114. PMID 39483736.
  4. ^ a b c Walker LC, Huckstep KL, Becker HC, Langmead CJ, Lawrence AJ (November 2024). "Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development". British Journal of Pharmacology. 181 (22): 4385–4398. doi:10.1111/bph.16081. PMID 37005377.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.